Conference Reports for NATAP

5th IAS Conference on HIV Pathogenesis, Treatment and Prevention July 19th-22nd 2009 Capetown, South Africa Back

Efficacy, safety and tolerability of dual therapy with raltegravir 400mg bid and atazanavir 200mg bid in antiretroviral experienced patients.       Reported by Jules Levin 5th IAS Capetown July 19-22 2009   D. Ripamonti1,2, F. Maggiolo1,2, E. Bombana2, G. Gregis1,2, G. Quinzan1,2, A. Callegaro3and F. Suter1,2 Antiviral Research Unit1, Infectious Diseases Unit2, Microbiology and Virology Unit3at Ospedali Riuniti di Bergamo, Italy RESULTS   Table 1: Baseline characteristics